Skip to main content
. Author manuscript; available in PMC: 2021 Mar 31.
Published in final edited form as: Lancet Oncol. 2020 Mar;21(3):e135–e145. doi: 10.1016/S1470-2045(19)30795-8

Figure 1: Timeline of US Food and Drug Administration approvals for the treatment of metastatic pancreatic cancer.

Figure 1:

Treatment options for metastatic pancreatic cancer placed on a timeline on the basis of their year of US Food and Drug Administration (FDA) approval. FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) and fluorouracil analogues in combination with gemcitabine are also included given their use in clinical practice, although no specific FDA approval has been obtained. Nab=nanoparticle albumin-bound.